E N D
ECS versus DES: TRIAS-HR 1 year Objective: to demonstrate non-inferiority of endothelialprogenitorcellcapturingstents(ECS) versus drugelutingstents (DES)Study: multicenter, randomizedstudyPopulation: patients with PCI of at least 1 targetlesionat high-risk of restenosis(smallvessel ≤ 2,8mm, lesionlength ≥ 20mm, CTO or lesion in DM patient)Endpoint: TLF and MACE: Cardiacdeath, MI or TLR
ECS versus DES: TRIAS-HR 1 year Conclusion ECS was not able to competewith DES in terms of restenosispreventionafter PCI of high-riskrestenosislesions Klomp JACC Interv 2011;4:896-904